InVivoMAb anti-mouse CD8beta (Lyt 3.2)

Howland SW, Poh CM, Rénia L. Activated Brain Endothelial Cells Cross-Present Malaria Antigen. PLoS Pathog. 2015,11(6):e1004963. doi: 10.1371/journal.ppat.1004963

Kobayashi T, Doff BL, Rearden RC, et al. NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma. Oncoimmunology. 2015,4(3):e990793.

Guillerey C, Ferrari de Andrade L, Vuckovic S, et al. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest. 2015,125(5):2077-89. doi: 10.1172/JCI77181

Allard B, Pommey S, Smyth MJ, et al. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013,19(20):5626-35. doi: 10.1158/1078-0432.CCR-13-0545

Verbrugge I, Hagekyriakou J, Sharp LL, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 2012,72(13):3163-74. doi: 10.1158/0008-5472.CAN-12-0210

Ahmed KA, Wang L, Munegowda MA, et al. Direct in vivo evidence of CD4+ T cell requirement for CTL response and memory via pMHC-I targeting and CD40L signaling. J Leukoc Biol. 2012,92(2):289-300. doi: 10.1189/jlb.1211631

Takada K, Jameson SC. Self-class I MHC molecules support survival of naive CD8 T cells, but depress their functional sensitivity through regulation of CD8 expression levels. J Exp Med. 2009,206(10):2253-69. doi: 10.1084/jem.20082553